Med2Date — Clinical Guidelines
Home Immunology Ag Presentation via MHC

Ag Presentation via MHC

Last updated 31 May 2026 · Immunology clinical guideline

📋 Key Information Summary

📋
  • Antigen presentation is the process by which peptide fragments are displayed on MHC molecules to activate T lymphocytes — the cornerstone of adaptive immunity.
  • MHC Class I (HLA-A, -B, -C) presents endogenous peptides from intracellular proteins to CD8⁺ cytotoxic T cells; expressed on virtually all nucleated cells.
  • MHC Class II (HLA-DR, -DQ, -DP) presents exogenous peptides from extracellular proteins internalised via endocytosis to CD4⁺ helper T cells; restricted to professional antigen-presenting cells.
  • The proteasome degrades cytosolic proteins into peptide fragments (8–10 amino acids) that are transported into the ER by TAP for loading onto MHC Class I.
  • The endolysosomal pathway degrades extracellular proteins into peptides (13–25 amino acids) for loading onto MHC Class II after CLIP removal by HLA-DM.
  • Cross-presentation allows dendritic cells to load exogenous antigens onto MHC Class I, bridging innate uptake and CD8⁺ T-cell activation — critical for anti-tumour and antiviral immunity.
  • Clinical deficiencies in the MHC pathway include Bare Lymphocyte Syndrome Type I (TAP deficiency) and Type II (CIITA/RFXANK defects), causing severe combined immunodeficiency.
  • HLA associations link specific alleles to autoimmune disease susceptibility (e.g., HLA-B27 with ankylosing spondylitis, HLA-DR4 with rheumatoid arthritis).
  • Transplant immunology depends on MHC matching — HLA-A, -B, -DR matching reduces rejection risk; mismatched donor organs require lifelong immunosuppression.
  • Tumour immune evasion frequently involves down-regulation of MHC Class I expression, enabling escape from CD8⁺ T-cell surveillance — a target for checkpoint immunotherapy.
  • Antiviral defence relies on MHC Class I presentation of viral peptides; viruses such as CMV and HIV encode immune-evasion proteins that interfere with TAP, tapasin, or MHC trafficking.
  • Pharmacogenomic HLA testing (e.g., HLA-B*57:01 for abacavir hypersensitivity, HLA-B*58:01 for allopurinol) is standard of care in Australia and subsidised through pathology MBS items.
  • Aboriginal and Torres Strait Islander populations have distinct HLA allele frequencies relevant to disease susceptibility and transplant matching programmes.

Introduction & Australian Context

Antigen presentation via major histocompatibility complex (MHC) molecules is the fundamental molecular mechanism by which immune cells display peptide fragments to T lymphocytes, enabling immune surveillance against infections, malignancy, and altered self. In humans, the MHC is encoded within the human leukocyte antigen (HLA) locus on chromosome 6p21.3 — the most polymorphic region in the human genome, with over 25,000 described alleles as of 2024.

The clinical significance of MHC-mediated antigen presentation extends across virtually every subspecialty of medicine. In Australia, HLA typing is integral to solid organ and haematopoietic stem cell transplantation, pharmacogenomic screening (abacavir, allopurinol, carbamazepine), autoimmune disease risk assessment, and emerging immunotherapeutic strategies for malignancy. Understanding the molecular pathways of antigen processing and presentation is therefore essential for clinicians managing immunodeficiency, transplant recipients, autoimmune conditions, and cancer.

This guideline provides a structured overview of the MHC Class I endogenous pathway, the MHC Class II exogenous pathway, cross-presentation mechanisms, and the clinical applications and disease associations relevant to Australian practice.

Ag Presentation via MHC clinical infographic — pathophysiology, clinical clues, diagnosis, imaging, and management
Tap or click image to enlarge — Ag Presentation via MHC: pathophysiology, clinical clues, diagnosis, imaging, and management.
Ag Presentation via MHC infographic, full size

MHC Class I Pathway (Endogenous)

The MHC Class I pathway presents peptides derived from intracellular (endogenous) proteins to CD8⁺ cytotoxic T lymphocytes (CTLs). This pathway enables immune surveillance of the intracellular proteome, detecting viral infection, intracellular bacteria, and tumour-associated neo-antigens.

Molecular Steps

  1. Protein synthesis and proteasomal degradation: Cytosolic proteins — including viral proteins, tumour antigens, and normal self-proteins — are ubiquitinated and degraded by the constitutive 26S proteasome (or the immunoproteasome, containing LMP2, LMP7, and MECL-1 subunits induced by IFN-γ) into peptide fragments of 8–25 amino acids.
  2. TAP transport: Peptides are translocated from the cytosol into the endoplasmic reticulum (ER) lumen by the Transporter Associated with Antigen Processing (TAP1/TAP2 heterodimer). TAP preferentially transports peptides of 8–16 amino acids with hydrophobic or basic C-terminal residues.
  3. MHC Class I assembly: Newly synthesised heavy chain (α chain) associates with β₂-microglobulin in the ER. The partially folded complex is stabilised by the peptide-loading complex (PLC) comprising tapasin, ERp57, and calreticulin.
  4. Peptide loading: Tapasin bridges the MHC Class I molecule to TAP, facilitating peptide editing — the exchange of low-affinity peptides for high-affinity binders. Only stably loaded MHC Class I–peptide complexes are released from the PLC.
  5. Surface transport: Stable MHC Class I–peptide complexes traverse the Golgi apparatus and are expressed on the cell surface, where they are surveyed by CD8⁺ T cells via the αβ T-cell receptor (TCR).

Expression Pattern

MHC Class I molecules (HLA-A, HLA-B, HLA-C in humans) are expressed on virtually all nucleated cells. Red blood cells and mature trophoblast cells have minimal or absent expression. Expression is upregulated by type I and type II interferons (IFN-α/β, IFN-γ), enhancing immune surveillance during infection.

ℹ️
Australian clinical note: IFN-γ upregulation of MHC Class I and the immunoproteasome is the basis for interferon-based therapies historically used in hepatitis B/C management and remains relevant in understanding checkpoint immunotherapy responses in melanoma — Australia's highest-incidence malignancy.

MHC Class II Pathway (Exogenous)

The MHC Class II pathway presents peptides derived from extracellular (exogenous) proteins to CD4⁺ helper T lymphocytes. This pathway is restricted to professional antigen-presenting cells (APCs) — dendritic cells, macrophages, and B lymphocytes — and is central to initiating and shaping adaptive immune responses.

Molecular Steps

  1. Antigen uptake: Professional APCs internalise extracellular antigens via receptor-mediated endocytosis (e.g., BCR on B cells, Fc receptors, C-type lectin receptors such as DC-SIGN and DEC-205), macropinocytosis, or phagocytosis.
  2. Endolysosomal processing: Internalised proteins are degraded in progressively acidified endosomal and lysosomal compartments by proteases including cathepsins (B, D, L, S) into peptide fragments of 13–25 amino acids.
  3. MHC Class II biosynthesis: MHC Class II α and β chains are synthesised in the ER and associate with the invariant chain (Ii; CD74). The Ii chain serves three functions: it prevents premature peptide binding, assists folding, and directs MHC Class II molecules to the endosomal compartment via its cytoplasmic targeting signals.
  4. CLIP removal and peptide loading: In the MHC Class II compartment (MIIC), the invariant chain is progressively degraded, leaving the CLIP (Class II-associated Invariant chain Peptide) fragment occupying the peptide-binding groove. HLA-DM catalyses the exchange of CLIP for antigenic peptides, acting as a peptide editor. HLA-DO modulates HLA-DM activity in B cells and thymic epithelium.
  5. Surface expression: Stable MHC Class II–peptide complexes are transported to the cell surface for presentation to CD4⁺ T cells.

Expression Pattern

Constitutive expression of MHC Class II (HLA-DR, HLA-DQ, HLA-DP) is largely restricted to professional APCs. However, expression can be induced on other cell types (epithelial cells, endothelial cells, fibroblasts) by IFN-γ via the transcription factor CIITA — a mechanism relevant to organ-specific autoimmune diseases such as thyroiditis and type 1 diabetes.

CD4⁺ T-Cell Subsets Activated by MHC Class II
T-Cell Subset Key Cytokines Function Clinical Relevance
Th1 IFN-γ, TNF-α, IL-2 Macrophage activation, intracellular pathogen clearance Granuloma formation (TB, leprosy); IFN-γ deficiency → NTM susceptibility
Th2 IL-4, IL-5, IL-13 B-cell class switching (IgE), eosinophil recruitment Allergic disease, helminth defence; overactivation → asthma/atopy
Th17 IL-17A, IL-17F, IL-22 Neutrophil recruitment, mucosal barrier defence Mucocutaneous candidiasis (STAT3/IL-17R defects); psoriasis, IBD
Tfh IL-21, IL-4 Germinal centre B-cell help, affinity maturation Antibody deficiency syndromes; vaccine responses
Treg IL-10, TGF-β, IL-35 Immune suppression, tolerance maintenance IPEX syndrome (FOXP3 mutation); transplant tolerance

Cross-Presentation

Cross-presentation is the specialised ability of certain dendritic cell (DC) subsets to load exogenous antigens onto MHC Class I molecules, enabling CD8⁺ T-cell activation against pathogens or tumour cells that the DC itself has not directly infected. This mechanism is essential for initiating cytotoxic responses against viruses that do not infect DCs and against tumour-associated antigens.

Two Major Pathways

Feature Vacuolar Pathway Cytosolic Pathway
Peptide generation site Endosome/phagosome Cytosol (proteasome)
Antigen escape Not required Endosome → cytosol (Sec61, lipid mediators)
TAP dependence Independent TAP-dependent (ER or phagosomal loading)
Proteasome dependence No (cathepsins) Yes
Primary DC subset CD8α⁻ DCs (human CD1c⁺) CD8α⁺ DCs (human CD141⁺/BDCA-3⁺)
Clinical significance Viral immunity, vaccines Anti-tumour immunity, viral defence

Key Molecular Regulators

  • NADPH oxidase (NOX2): Limits phagosomal acidification in DCs, preserving antigens for cross-presentation rather than complete lysosomal degradation.
  • Rac2 and VAMP8: Regulate recruitment of early endosomal components to phagosomes, favouring cross-presentation.
  • WDFY4: Recently identified as essential for cross-presentation in CD141⁺ DCs; WDFY4 deficiency impairs CD8⁺ T-cell priming.
  • IRAP (insulin-regulated aminopeptidase): Trims peptides in endosomes for MHC Class I loading in the vacuolar pathway.
⚠️
Therapeutic relevance: Cross-presentation is the immunological basis for most cancer vaccine strategies. Checkpoint inhibitors (anti-PD-1, anti-CTLA-4) are most effective when tumour antigens are cross-presented by CD141⁺ dendritic cells. Tumours that exclude DCs or inhibit cross-presentation (e.g., via VEGF, IL-10, or prostaglandin E₂ secretion) are immunologically "cold" and respond poorly to immunotherapy — a concept driving combination strategies with STING agonists, oncolytic viruses, and radiotherapy.

Clinical Relevance

Immunodeficiency — Defects in Antigen Presentation

Disorder Genetic Defect Pathway Affected Clinical Features Management
Bare Lymphocyte Syndrome Type I (BLS-I) TAP1, TAP2, or tapasin mutations MHC Class I loading Reduced CD8⁺ T cells; chronic necrotising granulomatous skin lesions; sinopulmonary infections Antibiotic prophylaxis; wound care; HSCT in severe cases
Bare Lymphocyte Syndrome Type II (BLS-II) CIITA, RFX5, RFXANK, RFXAP mutations MHC Class II transcription/assembly Absent MHC Class II expression; severe combined immunodeficiency; chronic diarrhoea, failure to thrive, opportunistic infections in infancy HSCT (curative); IVIg, antimicrobial prophylaxis pre-transplant
STAT1 GOF mutations STAT1 gain-of-function IFN-γ signalling (MHC Class II regulation) Chronic mucocutaneous candidiasis; vascular aneurysms; autoimmunity JAK inhibitors (ruxolitinib); antifungal prophylaxis; HSCT for refractory disease

HLA–Disease Associations

HLA Allele Associated Disease Relative Risk (OR) Proposed Mechanism
HLA-B27 Ankylosing spondylitis ~100–200 Arthritogenic peptide presentation; misfolding → UPR/IL-23; aberrant heavy-chain homodimers
HLA-DRB1*04:01 Rheumatoid arthritis ~5–10 Shared epitope binds citrullinated peptide; anti-CCP antibody generation
HLA-DQ2/DQ8 Coeliac disease ~7–20 Presentation of deamidated gliadin peptides to CD4⁺ T cells; tissue transglutaminase modifies peptides
HLA-DRB1*15:01 Multiple sclerosis ~3 Presentation of myelin-derived peptides (MBP, MOG)
HLA-B*57:01 Abacavir hypersensitivity ~900+ Altered peptide repertoire in the HLA-B*57:01 groove triggers CD8⁺ T-cell reaction
HLA-B*58:01 Allopurinol SJS/TEN ~40–80 Oxypurinol modifies peptide presentation; CD8⁺ T-cell-mediated cytotoxicity
HLA-A*31:01 Carbamazepine hypersensitivity ~10–25 Drug–peptide–HLA complex alters TCR recognition
✅
Australian PBS/MBS requirements: HLA-B*57:01 testing is mandatory prior to prescribing abacavir (PBS Authority Required). HLA-B*58:01 testing is recommended before allopurinol, particularly in patients of Southeast Asian or Polynesian ancestry. HLA typing for transplantation is available through Australian Red Cross Lifeblood and state histocompatibility laboratories. MBS item 71155 covers HLA typing by molecular methods.

Transplant Immunology

HLA matching is the foundation of solid organ and haematopoietic stem cell transplantation. In Australia, the national organ allocation system (managed by DonateLife and transplant organisations) uses HLA-A, -B, -DR matching as a key allocation criterion for renal transplantation. Zero-mismatch deceased donor kidneys are preferentially allocated to highly sensitised patients (cPRA >99%). For allogeneic HSCT, high-resolution HLA typing (10/10 match at HLA-A, -B, -C, -DRB1, -DQB1) is the standard, with haploidentical transplantation increasingly used when matched donors are unavailable.

Tumour Immune Evasion via MHC Down-regulation

Many tumours evade CD8⁺ T-cell surveillance by down-regulating MHC Class I expression through β₂-microglobulin mutations, epigenetic silencing of HLA genes, or TAP deficiency. This is observed in:

  • Melanoma: β₂-microglobulin loss is found in ~30–40% of metastatic melanomas progressing on checkpoint inhibitors.
  • Colorectal cancer: Microsatellite-unstable (MSI-H) tumours may develop β₂-microglobulin frameshift mutations.
  • Lung adenocarcinoma: HLA LOH (loss of heterozygosity) correlates with immune escape and poorer response to anti-PD-1 therapy.

Strategies to overcome MHC loss include combination immunotherapy, adoptive T-cell therapy with NK cells (which detect "missing self" via killer immunoglobulin-like receptors), and oncolytic virus therapy.

Vaccine Design and Antigen Presentation

Effective vaccines must generate peptides that are efficiently presented by common MHC alleles in the target population. The global shift towards peptide-based and mRNA vaccines (e.g., COVID-19 mRNA vaccines) leverages the MHC Class I pathway for CD8⁺ T-cell priming and the Class II pathway for CD4⁺ T-helper responses and antibody generation. Adjuvants (AS01, MF59, CpG-ODN) enhance antigen presentation by activating DCs and promoting MHC upregulation and co-stimulatory molecule expression.

Special Populations

🤰 Pregnancy
Trophoblast MHC expression
Extravillous trophoblast expresses HLA-G (non-classical MHC Class I) and HLA-C but lacks HLA-A, -B, and MHC Class II — enabling immune evasion of the semi-allogeneic foetus. HLA-G interacts with inhibitory receptors (ILT2, KIR2DL4) on uterine NK cells to promote tolerance. Recurrent miscarriage may be associated with aberrant HLA-G expression or polymorphisms.
HLA typing in obstetrics
Relevant for anti-D immunoglobulin prophylaxis monitoring and investigation of recurrent pregnancy loss. HLA-C matching between partners may influence pre-eclampsia risk via uterine NK cell KIR–HLA interactions.
👶 Paediatrics
Neonatal immune immaturity
Neonates have reduced MHC Class II expression on monocytes and impaired DC cross-presentation, contributing to susceptibility to intracellular pathogens (Listeria, HSV). MHC Class II expression matures over the first 6–12 months of life.
Bare Lymphocyte Syndrome Type II
Presents in infancy with severe opportunistic infections (PJP, CMV, chronic diarrhoea). Diagnosis requires flow cytometry for HLA-DR expression on monocytes and genetic testing. HSCT is curative if performed early.
🦠 Immunocompromised
HIV/AIDS
HIV Nef protein down-regulates HLA-A and HLA-B (but not HLA-C or HLA-E) from the cell surface, evading CTL recognition while avoiding NK cell activation. Elite controllers often have protective HLA alleles (B*57, B*27) presenting immunodominant Gag peptides.
Post-transplant immunosuppression
Calcineurin inhibitors (tacrolimus, cyclosporin) suppress NFAT-dependent IL-2 transcription, impairing T-cell responses to presented antigens. Anti-thymocyte globulin depletes T cells and modulates APC function. Understanding MHC presentation informs monitoring for CMV reactivation and PTLD.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health
HLA allele diversity
Aboriginal and Torres Strait Islander peoples have distinct HLA allele frequencies compared with non-Indigenous Australians, with some alleles (e.g., HLA-A*24:02, HLA-B*56:01) occurring at higher frequency. This has implications for transplant matching algorithms and pharmacogenomic screening programmes. National bone marrow donor registries must ensure adequate representation of Indigenous Australian HLA haplotypes.
Rheumatic fever and HLA
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) disproportionately affect Aboriginal and Torres Strait Islander peoples, particularly in northern and central Australia. HLA-DR7 and HLA-DR53 associations with ARF susceptibility have been described. Understanding MHC-restricted molecular mimicry between streptococcal M protein and cardiac myosin peptides informs vaccine development and risk stratification.
Pharmacogenomic equity
HLA-B*57:01 (abacavir) and HLA-B*58:01 (allopurinol) frequencies vary across populations. Ensuring equitable access to pre-prescription HLA testing in remote and very remote communities is essential. Point-of-care or dried blood spot testing for HLA alleles could reduce turnaround times and improve prescribing safety in areas without on-site laboratory facilities.
Infectious disease burden
Higher rates of rheumatic heart disease, invasive Group A Streptococcus disease, and chronic hepatitis B in Aboriginal and Torres Strait Islander communities intersect with HLA-mediated immune responses. Immune response heterogeneity to hepatitis B vaccination (associated with HLA-DR alleles) may partly explain variable vaccine efficacy in some populations — a factor relevant to the national hepatitis B elimination strategy.

📚 References

  1. 1. Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nature Reviews Immunology. 2011;11(12):823–836.
  2. 2. Joffre OP, Segura E, Savina A, Amigorena S. Cross-presentation by dendritic cells. Nature Reviews Immunology. 2012;12(8):557–569.
  3. 3. Blum JS, Wearsch PA, Cresswell P. Pathways of antigen processing. Annual Review of Immunology. 2013;31:443–473.
  4. 4. The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility complex. Nature. 1999;401(6756):921–923.
  5. 5. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 10th ed. Philadelphia: Elsevier; 2022.
  6. 6. Robinson J, Halliwell JA, Hayhurst JH, et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Research. 2015;43(Database issue):D423–D431.
  7. 7. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. New England Journal of Medicine. 2008;358(6):568–579.
  8. 8. Hung SI, Chung WH, Liou LB, et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proceedings of the National Academy of Sciences. 2005;102(11):4134–4139.
  9. 9. Fernando MMA, Stevens CR, Walsh EC, et al. Defining the role of the MHC in autoimmunity: a review. PLoS Genetics. 2008;4(4):e1000024.
  10. 10. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annual Review of Genomics and Human Genetics. 2013;14:301–323.
  11. 11. Australian Institute of Health and Welfare (AIHW). Aboriginal and Torres Strait Islander Health Performance Framework 2023. Canberra: AIHW; 2023.
  12. 12. RHDAustralia (a program of Menzies School of Health Research). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. 2020.
  13. 13. McLaren PJ, Carrington M. The impact of host genetic variation on HIV infection and disease outcomes. Nature Reviews Immunology. 2015;15(9):571–579.
  14. 14. McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259–1271.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).